Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome
Archives of Medical Science, 07/12/2011Yu DQ et al.
Atorvastatin therapy stabilized borderline vulnerable plaques and reversed atherosclerosis progression in patients with acute coronary syndrome (ACS). Reversal of this progression was accompanied by a decrease in the levels of plasma matrix metalloproteinase–9 (MMP–9) and hsCRP. Changes in MMP–9 and high–sensitive C–reactive protein (hsCRP) could predict vulnerable plaque stabilization.
Fifty patients with ACS whose culprit lesions were classified as “borderline lesions” were enrolled.
All patients were treated with atorvastatin (20 mg) for 12 months.
Intravascular ultrasound (IVUS) was performed and matrix metalloproteinase–9 (MMP–9), tissue inhibitor of metalloproteinase–1 (TIMP–1), and high–sensitive C–reactive protein (hsCRP) levels were measured at baseline and 12–month follow–up.
At 12–month follow–up, the authors found: 1) IVUS revealed that minimal lumen cross–sectional area (CSA) increased but plaque/media (P&M) area and plaque burden decreased.
A total of 25 soft plaques (50%) were transformed into fibrous plaques.
ApoB, MMP–9 and hsCRP levels decreased, but TIMP–1 level increased.
Stepwise multivariate linear regression analysis showed that the independent predictors for changes in P&M area/year were the decrease in MMP–9 and hsCRP levels.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.